PE59199A1 - Derivados de hidroxamato invertido como inhibidores de la metaloproteasa de matriz, inhibidores de la metaloproteasa, e inhibidores del tnf-alfa - Google Patents
Derivados de hidroxamato invertido como inhibidores de la metaloproteasa de matriz, inhibidores de la metaloproteasa, e inhibidores del tnf-alfaInfo
- Publication number
- PE59199A1 PE59199A1 PE1998000138A PE00013898A PE59199A1 PE 59199 A1 PE59199 A1 PE 59199A1 PE 1998000138 A PE1998000138 A PE 1998000138A PE 00013898 A PE00013898 A PE 00013898A PE 59199 A1 PE59199 A1 PE 59199A1
- Authority
- PE
- Peru
- Prior art keywords
- alkylene
- inhibitors
- metaloprotease
- tnf
- inverted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C07D285/135—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Detergent Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3911297P | 1997-02-26 | 1997-02-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE59199A1 true PE59199A1 (es) | 1999-06-24 |
Family
ID=21903750
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE1998000138A PE59199A1 (es) | 1997-02-26 | 1998-02-25 | Derivados de hidroxamato invertido como inhibidores de la metaloproteasa de matriz, inhibidores de la metaloproteasa, e inhibidores del tnf-alfa |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP1019386A1 (ja) |
| JP (1) | JP2001513767A (ja) |
| KR (1) | KR20000075681A (ja) |
| AP (1) | AP9901631A0 (ja) |
| AR (1) | AR013070A1 (ja) |
| AU (1) | AU6822398A (ja) |
| BR (1) | BR9807763A (ja) |
| CA (1) | CA2281664A1 (ja) |
| HR (1) | HRP980096A2 (ja) |
| IS (1) | IS5159A (ja) |
| NO (1) | NO994103L (ja) |
| PE (1) | PE59199A1 (ja) |
| PL (1) | PL335378A1 (ja) |
| TR (1) | TR199902063T2 (ja) |
| WO (1) | WO1998038179A1 (ja) |
| ZA (1) | ZA981532B (ja) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6294573B1 (en) | 1997-08-06 | 2001-09-25 | Abbott Laboratories | Reverse hydroxamate inhibitors of matrix metalloproteinases |
| US6235786B1 (en) | 1997-08-06 | 2001-05-22 | Abbott Laboratories | Reverse hydroxamate inhibitors of matrix metalloproteinases |
| PL194240B1 (pl) | 1998-02-07 | 2007-05-31 | British Biotech Pharm | Zastosowanie pochodnych N-formylohydroksyloaminy i amidowa pochodna N-formylohydroksyloaminy |
| GB9818621D0 (en) * | 1998-08-26 | 1998-10-21 | Glaxo Group Ltd | Formamide compounds as therapeutic agents |
| EP1121118A4 (en) * | 1998-08-26 | 2002-09-11 | Glaxo Group Ltd | FORMAMIDE-BASED THERAPEUTIC AGENTS |
| AU5688999A (en) * | 1998-08-26 | 2000-03-21 | Glaxo Group Limited | Formamide compounds as therapeutic agents |
| US6288261B1 (en) | 1998-12-18 | 2001-09-11 | Abbott Laboratories | Inhibitors of matrix metalloproteinases |
| US6329550B1 (en) | 1998-12-31 | 2001-12-11 | Aventis Pharmaceuticals Inc. | Amidomalonamides useful as inhibitors of MMP of matrix metalloproteinase |
| GB9918869D0 (en) * | 1999-08-10 | 1999-10-13 | British Biotech Pharm | Antibacterial agents |
| JP2003081838A (ja) * | 2001-09-11 | 2003-03-19 | Rohto Pharmaceut Co Ltd | グルコサミン製剤 |
| EP2319518A1 (en) | 2002-02-04 | 2011-05-11 | ALFAMA-Investigacao e Desenvolvimento de Produtos Farmaceuticos Lda. | Use of CO-releasing compounds for the manufacture of a medicament for the treatment of inflammatory diseases |
| CA2515534A1 (en) * | 2003-02-11 | 2004-08-26 | Boehringer Ingelheim International Gmbh | New pharmaceutical compositions based on anticholinergics and tace-inhibitors |
| EP1993583A4 (en) * | 2006-02-09 | 2010-06-23 | Burnham Inst | INHIBITORS OF MEMBRANE TYPE 1 TYPE MATRIX METALLOPROTEINASE FOR THE TREATMENT OF SUGAR DIABETES DEPENDING ON INSULIN |
| JP2011517313A (ja) | 2007-12-11 | 2011-06-02 | ビアメト ファーマシューティカルズ，インク． | 金属結合部分を標的化部分と組み合わせて使用する金属酵素阻害剤 |
| CA2719745C (en) | 2008-03-25 | 2016-07-05 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
| ATE541832T1 (de) | 2009-04-14 | 2012-02-15 | Affectis Pharmaceuticals Ag | Neuartige p2x7r-antagonisten und ihre verwendung |
| WO2012110190A1 (en) | 2011-02-17 | 2012-08-23 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
| PT2699242T (pt) | 2011-04-19 | 2018-01-22 | Alfama Inc | Moléculas de libertação de monóxido de carbono e utilizações das mesmas |
| WO2012163792A1 (en) | 2011-05-27 | 2012-12-06 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
| WO2012163456A1 (en) | 2011-05-27 | 2012-12-06 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
| WO2013013179A1 (en) | 2011-07-21 | 2013-01-24 | Alfama, Inc. | Ruthenium carbon monoxide releasing molecules and uses thereof |
| BR112021006407A8 (pt) | 2018-10-04 | 2022-12-06 | Inst Nat Sante Rech Med | uso de inibidores do egfr para ceratodermas |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9223904D0 (en) * | 1992-11-13 | 1993-01-06 | British Bio Technology | Inhibition of cytokine production |
| US6037472A (en) * | 1993-11-04 | 2000-03-14 | Syntex (U.S.A.) Inc. | Matrix metalloprotease inhibitors |
| EP0740652B1 (en) * | 1994-01-20 | 1998-05-06 | British Biotech Pharmaceuticals Limited | Metalloproteinase inhibitors |
| GB9514867D0 (en) * | 1995-07-20 | 1995-09-20 | British Biotech Pharm | Metalloproteinase inhibitors |
| HUP9903863A3 (en) * | 1995-11-23 | 2000-11-28 | British Biotech Pharm | Metalloproteinase inhibitors |
-
1998
- 1998-02-24 ZA ZA9801532A patent/ZA981532B/xx unknown
- 1998-02-24 WO PCT/EP1998/001015 patent/WO1998038179A1/en not_active Application Discontinuation
- 1998-02-24 PL PL98335378A patent/PL335378A1/xx unknown
- 1998-02-24 AU AU68223/98A patent/AU6822398A/en not_active Abandoned
- 1998-02-24 JP JP53728498A patent/JP2001513767A/ja active Pending
- 1998-02-24 HR HR60/039,112A patent/HRP980096A2/hr not_active Application Discontinuation
- 1998-02-24 CA CA002281664A patent/CA2281664A1/en not_active Abandoned
- 1998-02-24 BR BR9807763-5A patent/BR9807763A/pt not_active Application Discontinuation
- 1998-02-24 KR KR1019997007747A patent/KR20000075681A/ko not_active Application Discontinuation
- 1998-02-24 AP APAP/P/1999/001631A patent/AP9901631A0/en unknown
- 1998-02-24 EP EP98913575A patent/EP1019386A1/en not_active Withdrawn
- 1998-02-24 TR TR1999/02063T patent/TR199902063T2/xx unknown
- 1998-02-25 PE PE1998000138A patent/PE59199A1/es not_active Application Discontinuation
- 1998-02-25 AR ARP980100842A patent/AR013070A1/es unknown
-
1999
- 1999-08-20 IS IS5159A patent/IS5159A/is unknown
- 1999-08-25 NO NO994103A patent/NO994103L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO994103D0 (no) | 1999-08-25 |
| KR20000075681A (ko) | 2000-12-26 |
| NO994103L (no) | 1999-10-25 |
| PL335378A1 (en) | 2000-04-25 |
| EP1019386A1 (en) | 2000-07-19 |
| AR013070A1 (es) | 2000-12-13 |
| WO1998038179A1 (en) | 1998-09-03 |
| ZA981532B (en) | 1999-08-24 |
| CA2281664A1 (en) | 1998-09-03 |
| TR199902063T2 (xx) | 1999-12-21 |
| JP2001513767A (ja) | 2001-09-04 |
| IS5159A (is) | 1999-08-20 |
| HRP980096A2 (en) | 1998-12-31 |
| AU6822398A (en) | 1998-09-18 |
| BR9807763A (pt) | 2000-02-22 |
| AP9901631A0 (en) | 1999-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE59199A1 (es) | Derivados de hidroxamato invertido como inhibidores de la metaloproteasa de matriz, inhibidores de la metaloproteasa, e inhibidores del tnf-alfa | |
| TR200600172T1 (tr) | Solunum sistemi sinsitiyal virüsünün replikasyonunu inhibe edici maddeler. | |
| Wipf et al. | An improved protocol for azole synthesis with PEG-supported Burgess reagent | |
| ES467050A1 (es) | Un procedimiento para preparar derivados de prolina y com- puestos afines. | |
| HRP20010273A9 (en) | Two chamber cartridge for atomizers | |
| PE20090840A1 (es) | Moleculas pequenas que contienen boro | |
| EP0257102A4 (en) | Agents for treating neurophathy | |
| PE20020509A1 (es) | Aza y poliaza-naftalenil carboxamidas utiles como inhibidores de la integrasa del vih | |
| AU2017281525B2 (en) | Degradation of tripartite motif-containing protein 24 (TRIM24) by conjugation of TRIM24 inhibitors with E3 ligase ligand and methods of use | |
| AR036042A1 (es) | Derivados aralquilsufonil-3-(pirrol-2-ilmetiliden)-2-indolinona, sus composiciones farmaceuticas y metodo para la modulacion de la actividad catalitica de una proteina quinasa | |
| NZ511394A (en) | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | |
| AR050269A1 (es) | Derivados amino de urea ciclicos, su preparacion y su uso farmaceutico como inhibidores de quinasa | |
| HUP0101172A1 (hu) | Orto-antranilsavamid-származékok és antikoagulánsokként történő alkalmazásuk | |
| HUP0300850A2 (hu) | Gyűrűs béta-aminosav-származékok mint mátrix metalloproteázok és a TNF-alfa inhibitorok és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| PE20020819A1 (es) | COMPUESTOS DE PIRROLOTRIAZINA COMO INHIBIDORES DE CINASAS p38O Y ß | |
| PE20020228A1 (es) | Compuestos organicos como inhibidores de 3',5' guanosin monofosfato ciclico fosfodiesterasa | |
| PE20080267A1 (es) | Compuestos triarilicos y sus derivados | |
| EP0096517A3 (en) | Aryl pyrazinones | |
| AR034588A1 (es) | Derivados heterociclilalcoxi-, -alquiltio- y -alquilamino-benzazol como ligandos de 5-hidroxitriptamina-6, un proceso para su preparacion, intermediarios, composiciones farmaceuticas y el uso de dichos derivados para la manufactura de medicamentos | |
| BR0309357A (pt) | Método para fabricar cristais de esteróides, cristais obtìveis de acordo com esse método, e formulações farmacêuticas | |
| PE20020333A1 (es) | Derivados de pirrolidina como inhibidores de la enzima conversor de endotelina | |
| BR0316561A (pt) | Meios de filtração de sólidos de alta capacidade | |
| ATE407686T1 (de) | Medikament auf basis von honig, seine herstellung und verwendung | |
| PE20020339A1 (es) | Derivados de pirrolidin como inhibidores de las metaloproteasas | |
| ATE230725T1 (de) | Azetidinonderivate zur behandlung von hcmv entzündungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |